Scarica l'app Stockscreener
24.13
3.41%
0.8165
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Stifel raises Zymeworks stock price target on royalty deal value - Investing.com
Zymeworks Inc. (NASDAQ:ZYME) Q4 2025 Earnings Call Transcript - Insider Monkey
Citizens reiterates Zymeworks stock rating on strong cash position By Investing.com - Investing.com Canada
Decoding Zymeworks Inc (ZYME): A Strategic SWOT Insight - GuruFocus
Zymeworks (ZYME) Advances with Promising Zanidatamab Results - GuruFocus
Zymeworks (ZYME) Reveals Q4 Revenue Drop and Strategic Focus Shi - GuruFocus
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience - GuruFocus
Jefferies reiterates Zymeworks stock rating on financing deal - Investing.com
Zymeworks Secures $250 Million Non-Dilutive Royalty-Backed Financing from Royalty Pharma for Ziihera Royalties - Minichart
Zymeworks Inc. (ZYME) Posts Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - citybiz
Earnings call transcript: Zymeworks Q4 2025 shows revenue growth, net loss reduction - Investing.com UK
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens - AlphaStreet News
Zymeworks Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zymeworks secures $250M royalty financing from Royalty Pharma - Investing.com
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com
Zymeworks Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ZYME) 2026-03-02 - Seeking Alpha
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript - AOL.com
Zymeworks Monetizes Ziihera Royalties to Boost Liquidity - TipRanks
Zymeworks Posts Strong 2025 Growth and Bolsters Liquidity - TipRanks
Zymeworks 2025 10-K: $106M Revenue, $(1.08) EPS - TradingView
Zymeworks Inc. Q4 Loss Widens - Nasdaq
Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing - Stock Titan
Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma - Nasdaq
Zymeworks Inc. Reports Financial Results for 2025 and Updates on Ziihera® Development and Strategic Plans - Quiver Quantitative
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing - GlobeNewswire
Aug Levels: How sensitive is Zymeworks Inc to inflationMarket Sentiment Review & Verified Short-Term Trading Plans - baoquankhu1.vn
A Look Ahead: Zymeworks's Earnings Forecast - Benzinga
Zymeworks Inc. (ZYME) Stock Analysis: A High Upside Prospect with Promising Biotech Innovations - DirectorsTalk Interviews
Zymeworks Inc. (ZYME) Stock Analysis: Biotech Innovator With 56% Potential Upside - DirectorsTalk Interviews
Does Zymeworks Inc stock have upside surprise potential2025 Market Sentiment & Accurate Intraday Trade Tips - baoquankhu1.vn
Zymeworks (ZYME) Form 144 shows insider sell request of 31,641 shares - Stock Titan
How Zymeworks Inc. (ZYME) Affects Rotational Strategy Timing - Stock Traders Daily
How Zymeworks Inc. stock valuations compare to rivalsTrade Exit Summary & Long-Term Capital Growth Ideas - mfd.ru
What is Zymeworks Inc.’s TAM (Total Addressable Market)Long Setup & Precise Buy Zone Identification - mfd.ru
Zymeworks Inc. (ZYME) Stock Analysis: A Biotech Gem With 57% Potential Upside - DirectorsTalk Interviews
Should I average down on Zymeworks Inc. stockJuly 2025 Retail & Low Risk Entry Point Tips - mfd.ru
Is Zymeworks Inc.’s ROE strong enough2025 Short Interest & Precise Trade Entry Recommendations - mfd.ru
Zymeworks Sets Date for 2025 Results and Corporate Update - TipRanks
Zymeworks Inc. Scheduled to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 - GlobeNewswire
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes - MSN
Why Zymeworks Inc. (ZA8) stock is upgraded to buyJuly 2025 Highlights & Daily Price Action Insights - mfd.ru
Zymeworks (NASDAQ:ZYME) Trading 1.2% HigherTime to Buy? - MarketBeat
Aug PreEarnings: What is the dividend yield of AKOBMarket Activity Recap & Verified Stock Trade Ideas - baoquankhu1.vn
Zymeworks (ZYME): Biotech under pressure as investors wait for the next big catalyst - AD HOC NEWS
Tejara Capital Ltd Has $1.46 Million Stock Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Zymeworks Inc. (ZYME): Investor Outlook On A Promising Biotech With 59% Upside Potential - DirectorsTalk Interviews
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge - MSN
Zymeworks to Spotlight Pipeline and Portfolio at Series of Major Healthcare Investor Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Aug Volume: Should I set a stop loss on MOFGWeekly Investment Report & Weekly Momentum Picks - baoquankhu1.vn
Assessing Zymeworks (ZYME) Valuation After Major Leadership And Board Reshuffle - Sahm
Stop Loss: Can BHST expand its profit marginsJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Zymeworks Inc. (ZYME) Stock Analysis: Strong Buy Ratings and a Promising 51% Upside Potential - DirectorsTalk Interviews
Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare ConferenceSlideshow - Seeking Alpha
Analyst Upgrade: Does Zymeworks Inc have strong EBITDA marginsPortfolio Risk Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Does Zymeworks’ HERIZON-GEA-01 Win And Milestone Potential Change The Bull Case For ZYME? - Sahm
Analysts Are Bullish on Top Healthcare Stocks: Zymeworks (ZYME), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Zymeworks to Showcase Innovative Biotherapeutics at Upcoming Conferences - MSN
1.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):